DK3478712T3 - Anti-N3pGlu-amyloidbetapeptid-antistoffer og anvendelser deraf - Google Patents
Anti-N3pGlu-amyloidbetapeptid-antistoffer og anvendelser deraf Download PDFInfo
- Publication number
- DK3478712T3 DK3478712T3 DK17736841.2T DK17736841T DK3478712T3 DK 3478712 T3 DK3478712 T3 DK 3478712T3 DK 17736841 T DK17736841 T DK 17736841T DK 3478712 T3 DK3478712 T3 DK 3478712T3
- Authority
- DK
- Denmark
- Prior art keywords
- amyloid beta
- beta peptide
- peptide antibodies
- n3pglu amyloid
- n3pglu
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662357579P | 2016-07-01 | 2016-07-01 | |
| PCT/US2017/038999 WO2018005282A1 (en) | 2016-07-01 | 2017-06-23 | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3478712T3 true DK3478712T3 (da) | 2023-09-04 |
Family
ID=59295341
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK17736841.2T DK3478712T3 (da) | 2016-07-01 | 2017-06-23 | Anti-N3pGlu-amyloidbetapeptid-antistoffer og anvendelser deraf |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US11312763B2 (da) |
| EP (2) | EP3478712B1 (da) |
| JP (4) | JP7165588B2 (da) |
| KR (3) | KR20230021773A (da) |
| CN (3) | CN114887054A (da) |
| AU (1) | AU2017291414B2 (da) |
| BR (1) | BR112018073843A2 (da) |
| CA (1) | CA3029550C (da) |
| DK (1) | DK3478712T3 (da) |
| EA (1) | EA201892690A1 (da) |
| ES (1) | ES2958508T3 (da) |
| FI (1) | FI3478712T3 (da) |
| HR (1) | HRP20230861T1 (da) |
| HU (1) | HUE062980T2 (da) |
| IL (1) | IL263788A (da) |
| LT (1) | LT3478712T (da) |
| MA (1) | MA45543B1 (da) |
| MD (1) | MD3478712T2 (da) |
| MX (2) | MX2018016066A (da) |
| PL (1) | PL3478712T3 (da) |
| PT (1) | PT3478712T (da) |
| RS (1) | RS64386B1 (da) |
| SG (1) | SG11201810371XA (da) |
| SI (1) | SI3478712T1 (da) |
| TW (2) | TWI735600B (da) |
| UA (1) | UA127101C2 (da) |
| WO (1) | WO2018005282A1 (da) |
| ZA (1) | ZA201807633B (da) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI735600B (zh) | 2016-07-01 | 2021-08-11 | 美商美國禮來大藥廠 | 抗－N3pGlu類澱粉β肽抗體及其用途 |
| JOP20190247A1 (ar) | 2017-04-20 | 2019-10-20 | Lilly Co Eli | أجسام بيتا ببتيد النشوانية المضادة لـ N3pGlu واستخداماتها |
| EP3521308B1 (en) * | 2018-01-31 | 2024-03-13 | Vivoryon Therapeutics N.V. | Humanized and de-immunized antibodies |
| WO2019169448A1 (en) * | 2018-03-09 | 2019-09-12 | St Vincent's Institute Of Medical Research | Multi-specific antibodies |
| CN112805031A (zh) * | 2018-07-24 | 2021-05-14 | 卫材R&D管理有限公司 | 阿尔茨海默病的治疗及预防方法 |
| CN111184725B (zh) * | 2020-02-27 | 2020-12-01 | 慈溪市人民医院医疗健康集团(慈溪市人民医院) | 一种防治脑梗塞的药物制剂及其制备方法 |
| TW202243690A (zh) * | 2021-01-11 | 2022-11-16 | 美商美國禮來大藥廠 | 抗N3pGlu類澱粉β抗體及其用途 |
| WO2022251048A1 (en) | 2021-05-24 | 2022-12-01 | Eli Lilly And Company | Anti-amyloid beta antibodies and uses thereof |
| WO2023076970A1 (en) * | 2021-10-29 | 2023-05-04 | Eli Lilly And Company | Compounds and methods targeting interleukin-34 |
| JP2023067832A (ja) * | 2021-10-29 | 2023-05-16 | イーライ リリー アンド カンパニー | インターロイキン－３４を標的とする化合物及び方法 |
| WO2023146818A2 (en) * | 2022-01-26 | 2023-08-03 | T3D Therapeutics, Inc. | Methods of treating amyloid related brain disorders using novel compounds and antibodies |
| WO2023150483A1 (en) * | 2022-02-03 | 2023-08-10 | Eli Lilly And Company | Regional tau imaging for diagnosing and treating alzheimer's disease |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1397539A (en) * | 1920-01-14 | 1921-11-22 | Odell Risdon Moore | Egg-carton |
| CN101670105B (zh) | 2000-02-24 | 2014-08-06 | 华盛顿大学 | 螯合淀粉样蛋白β肽的人源化抗体 |
| US7122374B1 (en) | 2002-04-09 | 2006-10-17 | Takaomi Saido | Amyloid beta-protein 3(pE)-42 antibodies and uses thereof |
| AU2003250102B2 (en) | 2002-07-24 | 2009-09-17 | Innogenetics N.V. | Fragments of beta-amyloid as targets for vaccination against alzheimer disease |
| CA2538220A1 (en) | 2003-09-09 | 2005-03-24 | Takeda Pharmaceutical Company Limited | Use of antibody |
| MX2007000998A (es) | 2004-07-30 | 2007-07-11 | Rinat Neuroscience Corp | Anticuerpos dirigidos peptido beta-amiloide y procedimientos que usan los mismos. |
| PE20100684A1 (es) | 2005-12-12 | 2010-10-04 | Hoffmann La Roche | Anticuerpo anti b-4-amiloide que contiene asparagina glicosilada en la region variable de vh |
| KR101413615B1 (ko) | 2006-03-23 | 2014-07-18 | 바이오악틱 뉴로사이언스 에이비 | 인간 프로토피브릴에 선택적인 개선된 항체 및 이의 용도 |
| AR062065A1 (es) | 2006-07-14 | 2008-10-15 | Ac Immune Sa | Anticuerpo humanizado |
| LT2842967T (lt) | 2007-01-18 | 2017-02-27 | Eli Lilly And Company | Beta amiloido pegilintas fab |
| PL2182983T3 (pl) * | 2007-07-27 | 2014-10-31 | Janssen Alzheimer Immunotherap | Leczenie chorób amyloidowych z wykorzystaniem humanizowanych przeciwciał specyficznych względem Abeta |
| MX2010013647A (es) | 2008-06-12 | 2011-04-05 | Affiris Ag | Compuestos para tratar sintomas asociados con la enfermedad de parkinson. |
| EP2321348A2 (en) | 2008-07-09 | 2011-05-18 | University of Zürich | Method of promoting neurogenesis |
| WO2010009987A2 (en) | 2008-07-21 | 2010-01-28 | Probiodrug Ag | Diagnostic antibody assay |
| CN101397539B (zh) * | 2008-10-14 | 2011-10-05 | 中国人民解放军第三军医大学 | 组织工程组织仿生培养的模拟人体生理应力的施力装置 |
| UA108363C2 (uk) | 2009-10-08 | 2015-04-27 | Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування | |
| US8795664B2 (en) | 2010-06-04 | 2014-08-05 | Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin | Monoclonal antibodies targeting amyloid beta oligomers |
| WO2012021475A2 (en) | 2010-08-12 | 2012-02-16 | Eli Lilly And Company | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF |
| PL3339323T3 (pl) * | 2010-08-12 | 2020-05-18 | Eli Lilly And Company | Przeciwciała przeciwko peptydowi N3pGlu amyloidu beta i ich zastosowania |
| US9499610B2 (en) | 2011-04-08 | 2016-11-22 | H. Lundbeck A/S | Antibodies specific to pyroglutamated Aβ |
| EP2928494A4 (en) | 2012-12-07 | 2016-11-02 | Biogen Internat Neuroscience Gmbh | METHOD FOR REDUCING AMYLOIDER PLAQUE OF BRAIN WITH ANTI-ASS ANTIBODIES |
| TWI593692B (zh) | 2013-03-12 | 2017-08-01 | 美國禮來大藥廠 | 四氫吡咯并噻嗪化合物 |
| MX2016010237A (es) | 2014-02-08 | 2017-04-27 | Genentech Inc | Metodos de tratamiento de enfermedad de alzheimer. |
| WO2015175769A1 (en) | 2014-05-15 | 2015-11-19 | Biogen Ma Inc. | Methods for the detection of amyloid beta oligomers in biological samples |
| WO2015191825A1 (en) * | 2014-06-13 | 2015-12-17 | Biogen Ma Inc. | Methods for the detection and measurement of amyloid beta in biological samples |
| JP6201928B2 (ja) * | 2014-08-04 | 2017-09-27 | トヨタ自動車株式会社 | 車両制御装置 |
| TWI570127B (zh) | 2014-09-15 | 2017-02-11 | 美國禮來大藥廠 | 結晶型N-[3-[(4aR,7aS)-2-胺基-6-(5-氟嘧啶-2-基)-4,4a,5,7-四氫吡咯并[3,4-d][1,3]噻嗪-7a-基]-4-氟-苯基]-5-甲氧基-吡嗪-2-甲醯胺、其用途及醫藥組合物 |
| TWI599358B (zh) * | 2014-09-16 | 2017-09-21 | 美國禮來大藥廠 | 組合療法 |
| WO2016053767A1 (en) | 2014-09-30 | 2016-04-07 | Merck Sharp & Dohme Corp. | Novel crystalline forms of a bace inhibitor, compositions, and their use |
| MA41115A (fr) * | 2014-12-02 | 2017-10-10 | Biogen Int Neuroscience Gmbh | Procédé de traitement de la maladie d'alzheimer |
| JOP20170004B1 (ar) | 2016-01-15 | 2022-09-15 | Lilly Co Eli | الأجسام المضادة لببتيد بيتا النشوي مضاد N3pGlu واستخداماته |
| TWI735600B (zh) | 2016-07-01 | 2021-08-11 | 美商美國禮來大藥廠 | 抗－N3pGlu類澱粉β肽抗體及其用途 |
-
2017
- 2017-06-16 TW TW106120115A patent/TWI735600B/zh active
- 2017-06-16 TW TW110125726A patent/TWI798751B/zh active
- 2017-06-23 ES ES17736841T patent/ES2958508T3/es active Active
- 2017-06-23 MD MDE20190551T patent/MD3478712T2/ro unknown
- 2017-06-23 EP EP17736841.2A patent/EP3478712B1/en active Active
- 2017-06-23 KR KR1020237004025A patent/KR20230021773A/ko not_active Application Discontinuation
- 2017-06-23 KR KR1020187037757A patent/KR102221402B1/ko active IP Right Grant
- 2017-06-23 JP JP2018567740A patent/JP7165588B2/ja active Active
- 2017-06-23 DK DK17736841.2T patent/DK3478712T3/da active
- 2017-06-23 AU AU2017291414A patent/AU2017291414B2/en active Active
- 2017-06-23 UA UAA201811726A patent/UA127101C2/uk unknown
- 2017-06-23 WO PCT/US2017/038999 patent/WO2018005282A1/en unknown
- 2017-06-23 US US16/310,629 patent/US11312763B2/en active Active
- 2017-06-23 PT PT177368412T patent/PT3478712T/pt unknown
- 2017-06-23 CN CN202210683585.6A patent/CN114887054A/zh active Pending
- 2017-06-23 MX MX2018016066A patent/MX2018016066A/es unknown
- 2017-06-23 EP EP23176986.0A patent/EP4272828A3/en active Pending
- 2017-06-23 FI FIEP17736841.2T patent/FI3478712T3/fi active
- 2017-06-23 BR BR112018073843-3A patent/BR112018073843A2/pt unknown
- 2017-06-23 CN CN201780040635.6A patent/CN109415433A/zh active Pending
- 2017-06-23 CA CA3029550A patent/CA3029550C/en active Active
- 2017-06-23 KR KR1020217005333A patent/KR20210024213A/ko not_active IP Right Cessation
- 2017-06-23 MA MA45543A patent/MA45543B1/fr unknown
- 2017-06-23 LT LTEPPCT/US2017/038999T patent/LT3478712T/lt unknown
- 2017-06-23 RS RS20230595A patent/RS64386B1/sr unknown
- 2017-06-23 SI SI201731389T patent/SI3478712T1/sl unknown
- 2017-06-23 EA EA201892690A patent/EA201892690A1/ru unknown
- 2017-06-23 PL PL17736841.2T patent/PL3478712T3/pl unknown
- 2017-06-23 HU HUE17736841A patent/HUE062980T2/hu unknown
- 2017-06-23 SG SG11201810371XA patent/SG11201810371XA/en unknown
- 2017-06-23 HR HRP20230861TT patent/HRP20230861T1/hr unknown
- 2017-06-23 CN CN202210683554.0A patent/CN114917338A/zh active Pending
-
2018
- 2018-11-13 ZA ZA2018/07633A patent/ZA201807633B/en unknown
- 2018-12-18 MX MX2023001299A patent/MX2023001299A/es unknown
- 2018-12-18 IL IL263788A patent/IL263788A/en unknown
-
2020
- 2020-12-03 JP JP2020201051A patent/JP2021059547A/ja active Pending
- 2020-12-03 JP JP2020201050A patent/JP7241058B2/ja active Active
-
2022
- 2022-04-01 US US17/711,099 patent/US20220235122A1/en active Pending
-
2023
- 2023-06-06 JP JP2023093033A patent/JP2023123503A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202007868B (en) | Anti-n3pglu amyloid beta peptide antibodies and uses thereof | |
| DK3478712T3 (da) | Anti-N3pGlu-amyloidbetapeptid-antistoffer og anvendelser deraf | |
| DK3383916T3 (da) | Anti-CD73-antistoffer og anvendelser deraf | |
| ZA201901207B (en) | Anti-n3pglu amyloid beta peptide antibodies and uses thereof | |
| DK3458479T3 (da) | Anti-b7-h3-antistoffer og antistof-lægemiddelkonjugater | |
| KR102162129B9 (ko) | 항-갈렉틴-9 항체 및 이의 용도 | |
| DK3443009T3 (da) | Anti-tim-3-antistoffer og sammensætninger | |
| DK3283106T3 (da) | Terapeutiske antistoffer og anvendelser deraf | |
| DK3459597T3 (da) | Enkeltdomæne-antistof mod ctla4 og deraf afledt protein | |
| DK3274370T3 (da) | Anti-ceacam6-antistoffer og anvendelser deraf | |
| DK3307274T3 (da) | Anti-cd123-antistoffer og konjugater deraf | |
| DK3365368T3 (da) | Tgfbeta1-bindende immunoglobuliner og anvendelse deraf | |
| DK3350220T3 (da) | Anti-pro/latente-myostatin-antistoffer og anvendelser deraf | |
| DK3463435T3 (da) | Alpha-synuklein-antistoffer og anvendelser deraf | |
| DK3504242T3 (da) | Anti-ox40-antistoffer og anvendelse deraf | |
| DK3353212T3 (da) | Optimerede bispecifikke anti-CD3-antistoffer og anvendelser deraf | |
| DK3303395T3 (da) | Anti-cd40-antistoffer og anvendelser deraf | |
| DK3258951T3 (da) | Anti-pvrig antistoffer og fremgangsmåder for anvendelse | |
| DK3333191T3 (da) | Anti-C10ORF54-antistoffer og anvendelser deraf | |
| DK3313884T3 (da) | Anti-cd123-antistoffer og konjugater og derivater deraf | |
| DK3126388T3 (da) | Anti-EGFRvIII-antistoffer og anvendelser deraf | |
| DK3532499T3 (da) | ANTI-IL-33-antistoffer og anvendelser deraf | |
| DK3157552T3 (da) | Syntac-polypeptider og anvendelser deraf | |
| DK3402821T3 (da) | Psma-bindende antistof og anvendelser deraf | |
| DK3261720T3 (da) | Antistoffer til tau og anvendelser deraf |